FL-ELEVATE-PRIZE
4.11.2021 17:02:13 CET | Business Wire | Press release
The Elevate Prize Foundation, in collaboration with MIT Solve, announced today the winners of the second annual Elevate Prize, which distributes $5 million across 10 diverse social entrepreneurs working to solve pressing issues around the world. This year’s winners, selected from a pool of over 1,200 applicants, stand out for their innovative approaches to global causes, such as LGBTQIA+ rights, access to health care, social justice reform and sustainability.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211104005942/en/
Founded in 2019 by Joseph Deitch, The Elevate Prize Foundation aims to “Make Good Famous” by partnering with rising activists and social entrepreneurs and providing them with resources to raise visibility of their work, multiplying their ability to mobilize support – whether online or on-the-ground. The 2021 winners of the Elevate Prize will each receive a minimum of $300,000 in prize funding, as well as leadership development services, social media training, mentorship, and other support needed to reach a wider audience and grow their following.
“This year’s Elevate Prize winners are an exceptional group of creative problem-solvers who have managed to catalyze change through such challenging times,” said Joseph Deitch, Founder, Elevate Prize Foundation. “In a world that is increasingly looking for leaders to lead … and to inspire us, we are so fortunate to have these incredible individuals and organizations show us the way. We look forward to partnering and co-creating with them to expand their impact, and to share their stories with the world.”
The winners of the 2021 Elevate Prize are:
- Amanda Alexander, Detroit Justice Center , which works alongside communities to transform the justice system and promote equitable and fair cities.
- Krista Donaldson, Equalize Health , which provides access to medical care and addresses the leading causes of maternal and newborn mortality through innovative tech.
- Aparna Hegde, ARMMAN , which uses mobile technology to enable healthy pregnancies, safe deliveries, and healthy childhoods.
- Kaushik Kappangantulu, Kheyti , which designs, adapts and implements low-cost farming solutions to help farmers increase yield and predictability of produce, offering a “greenhouse-in-a-box” – an affordable, modular greenhouse bundled with full-stack services.
- Nisha Ligon, Ubongo , the leading children’s entertainment producer in Africa, which harnesses the power of entertainment to reduce inequalities in education across Africa.
- Heejae Lim, TalkingPoints , which connects and empowers families in under-resourced, multilingual communities, using communications technology to bridge crucial gaps between students, families, teachers, and schools.
- Uzoma Orchingwa , Ameelio , which works to reduce the prison population, decrease recidivism and ensure incarcerated individuals can stay in touch with the outside through free-to-use communication apps.
- Alexander Roque, Ali Forney Center , a space dedicated to empowering homeless LGBTQIA+ youth to live independently and get back on their feet.
- Rebecca van Bergen, Nest , which supports the responsible growth and creative engagement of the artisan and maker economy to build a world of greater gender equity and economic inclusion.
- Tony Weaver , Weird Enough Productions , which runs a national education program that combines diverse comic books with an anti-racist and equity-based learning curricula.
“We’re thrilled to highlight such a radically diverse group of winners this year, all working on a wide-range of important issues around the world,” said Carolina García Jayaram, CEO of The Elevate Prize Foundation. “We look forward to helping grow their audience and impact, ultimately making philanthropy and social change more accessible to all.”
The Elevate Prize 2021 winners were selected by a renowned judging panel, composed of purpose-driven leaders in business, academia, media and beyond, including Diane von Furstenberg, fashion designer and philanthropist; Maria Elena Salinas, journalist and CBS news contributor; Stephanie Mehta, Editor-in-Chief of Fast Company; and Natalie Tran, Executive Director of the CAA Foundation.
About The Elevate Prize Foundation
Founded in 2019 by businessman, philanthropist, and author Joseph Deitch, The Elevate Prize Foundation aims to serve as an engine for social good by funding, guiding, and scaling the platforms of social entrepreneurs. The Foundation’s signature program is its annual Elevate Prize, which is awarded to 10 or more global leaders tackling pressing issues in innovative ways. The Elevate Prize Catalyst Award, another one of the Foundation’s programs, recognizes prominent individuals for their commitment to inspiring global social action and using their influence for the good of humanity. Through the Elevate Giving program, the Foundation allows everyday people the opportunity to engage in philanthropy. For more information, visit www.elevateprize.org and follow @ElevatePrize on Facebook , Instagram , LinkedIn , and Twitter .
About MIT Solve
Solve is an initiative of the Massachusetts Institute of Technology (MIT) with a mission to solve world challenges. Solve is a marketplace for social impact innovation. Through open innovation Challenges, Solve finds incredible tech-based social entrepreneurs all around the world. Solve then brings together MIT’s innovation ecosystem and a community of Members to fund and support these entrepreneurs to help them drive lasting, transformational impact. Join Solve on this journey at solve.mit.edu .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211104005942/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Two-Year Data of Pimicotinib Demonstrated Durable Tumor Control and Sustained Improvement in TGCT Symptoms and Joint Function26.10.2026 12:00:00 CET | Press release
Improvements in symptoms of pain, stiffness, and range of motion were sustained through two yearsTumor responses remained robust1 and durable2Not intended for U.K.-, U.S.- or Canada-based media Merck, a leading science and technology company, today announced new two-year follow-up results from the Phase 3 MANEUVER study evaluating pimicotinib in patients with tenosynovial giant cell tumor (TGCT). The study showed that among patients initially randomized to pimicotinib, improvements in symptoms and joint function were observed as early as Week 5, sustained through two years, and continued to improve over time. Tumor responses remained robust1 and durable,2 and the safety profile was consistent with previous analyses. The findings are being presented today in the Sarcoma poster session at the European Society for Medical Oncology (ESMO) Congress 2026 (Presentation # 3747P). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022
WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN26.10.2026 11:30:00 CET | Press release
Second limited-edition WHOOP x SR_A collection brings “performance for life” to new WHOOP bands, technical apparel, outerwear, and accessories designed for movement across city and rural environments. WHOOP, the human performance brand, today announced Layer 2 of PROJECT TERRAIN, its multiyear collaboration with British designer Samuel Ross MBE and his design atelier, SR_A. Building on the sold out debut collection launched in March 2026, Layer 2 expands PROJECT TERRAIN to its next season connecting lifestyle and performance for movement, adaptability and zone based training. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261026029587/en/ WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN While the first PROJECT TERRAIN collection harnessed dense cities and modern training grounds, Layer 2 explores performance through material, silhouette and tactility. Drawing on the textures, conditions, and flux of the natural wo
Bleeding gums? Don't ignore the warning signs – the first stage of gum disease can be reversed26.10.2026 11:28:00 CET | Press release
Oral-B iO helps you avoid new tooth and gum issues—and if you have existing gum problems, it can resolve them quicker than a manual toothbrush. Gums bleeding when brushing can happen to any of us, and it is easy to ignore. But blood in the sink is a sign that something is not right with your mouth. Bleeding gums often indicate gingivitis, the earliest and most common form of gum disease. The good news: gingivitis can be reversed with proper oral hygiene. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022835650/en/ Oral-B iO Left untreated, gingivitis can progress into periodontitis, a more severe stage of gum disease that can only be managed, not reversed, and can lead to losing teeth over time. Healthy gums matter beyond the mouth, too. Oral health and systemic health are deeply interconnected, with inflammation and bacteria from oral diseases contributing to conditions such as heart disease, diabetes and dementia. "Gums
Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 08:00:00 CET | Press release
Clinical and preclinical presentations reflect the company’s ongoing exploration of peripheral neuropathic pain Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greates
Andersen Consulting tilføjer samarbejdsfirmaet TechSparq25.10.2026 06:09:00 CET | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med TechSparq, en amerikansk virksomhed, der kombinerer strategi, commerce engineering og ai med praktisk implementering. TechSparq er et digitalt konsulenthus, der tilbyder strategi- og rådgivningstjenester, commerce engineering samt tjenester inden for ai og agentbaseret handel til virksomheder inden for detailhandel og forbrugsgoder, luksus og mode samt e-handel og direkte salg til forbrugere. Virksomheden har hovedkontor i Oregon og kombinerer strategisk planlægning med praktisk implementering for at hjælpe kunderne med at udvikle deres digitale initiativer, kundeoplevelse og driftsmodeller. "Vi etablerede vores virksomhed for at bygge bro mellem dem, der udvikler strategien, og dem, der har ansvaret for at føre den ud i livet," udtalte Dedrick Boyd, stifter af og administrerende direktør for TechSparq. "Vores samarbejde med Andersen Consulting giver os mulighed
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
